prostate cancer

Janssen Shows 35% Drop in Mortality with Prostate Cancer Drug
BioSpace
Wed, 02/10/21 - 12:01 am
Janssen
JNJ
Erleada
prostate cancer
clinical trials
Merck and AstraZeneca's Cancer Drug Wins 3 New Approvals in Japan
Motley Fool
Tue, 12/29/20 - 10:57 am
Merck
AstraZeneca
Japan
ovarian cancer
prostate cancer
pancreatic cancer
Lynparza
Myovant Up on $4.2B Pfizer Pact to Develop Prostate-Cancer Drug
TheStreet.com
Mon, 12/28/20 - 10:42 am
Myovant
Pfizer
prostate cancer
Orgovyx
Relugolix
In groundbreaking move, FDA approves Myovant's relugolix as the first once-a-day pill for advanced prostate cancer
Endpoints
Sat, 12/19/20 - 11:24 pm
Myovant Sciences
Relugolix
FDA
prostate cancer
Orgovyx
J&J taps the bispecific experts at Xencor for prostate cancer discovery pact, kicking off with $50M upfront
Endpoints
Mon, 12/7/20 - 10:45 am
JNJ
Xencor
Janssen
bispecific antibodies
prostate cancer
Novartis bet $6B on the idea — now Versant, venBio have $45M to birth a platform play for radiopharmaceuticals
Endpoints
Wed, 10/14/20 - 10:51 am
Versant Ventures
PSMA-617
radiopharmaceuticals
prostate cancer
Novartis
Rayze Bio
venBio
Myovant shows disappointing prostate cancer data on the way to the FDA, stock sinks
Endpoints
Tue, 09/29/20 - 12:13 pm
Myovant
Relugolix
prostate cancer
AbbVie
Lupron
clinical trials
Valirx eyes partnerships as first VAL201 study hits the mark
Pharmaforum
Mon, 09/28/20 - 10:40 am
Valirx
VAL201
prostate cancer
clinical trials
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
Fierce Biotech
Sun, 09/20/20 - 08:02 pm
Roche
prostate cancer
ESMO
JNJ
Ipatasertib
Zytiga
Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold
Fierce Biotech
Tue, 08/18/20 - 11:05 pm
Poseida Therapeutics
solid tumors
CAR-T
SEC
prostate cancer
AI algorithm for detecting prostate cancer shows more than 98% sensitivity, 97% specificity in study
MedCity News
Wed, 07/29/20 - 10:47 am
Ibex Medical Analytics
diagnostics
artificial intelligence
prostate cancer
Looking at a groundbreaking advance, Myovant gets a priority review at FDA
Endpoints
Mon, 06/22/20 - 11:10 am
Myovant
FDA
priority review
Relugolix
prostate cancer
Roche phase 3 hits goal in subgroup of prostate cancer patients
Fierce Biotech
Fri, 06/19/20 - 11:29 am
Roche
clinical trials
Ipatasertib
prostate cancer
The ipatasertib curate’s egg
EP Vantage
Fri, 06/19/20 - 10:45 am
Roche
akt protein inhibitor
prostate cancer
Ipatasertib
ASCO: Myovant details speedy effects of prostate cancer med relugolix
Fierce Biotech
Mon, 06/1/20 - 10:45 am
Myovant
ASCO 2020
Relugolix
prostate cancer
clinical trials
FDA Approves New Prostate Cancer Treatment From AstraZeneca and Merck
Motley Fool
Wed, 05/20/20 - 11:23 pm
AstraZeneca
Merck
Lynparza
prostate cancer
FDA
Clovis steals march on AZ with PARP prostate approval
Pharmaforum
Mon, 05/18/20 - 10:44 am
Clovis Oncology
prostate cancer
Rubraca
FDA
ASCO: Arvinas unveils first-in-human data for novel protein degrader in prostate cancer
Fierce Biotech
Thu, 05/14/20 - 11:56 am
ASCO 2020
Arvinas
ARV-110
protein degradation
prostate cancer
Go or no go? Oncology dominates upcoming decisions
EP Vantage
Fri, 05/1/20 - 11:09 am
FDA
oncology
AstraZeneca
Lynparza
ovarian cancer
prostate cancer
Bristol-Myers Squibb
Opdivo
lung cancer
Positive Prostate Cancer Results for Lynparza Are Bad News for Clovis Oncology
Motley Fool
Mon, 04/27/20 - 07:27 pm
Clovis Oncology
Rubraca
AstraZeneca
Merck
Lynparza
prostate cancer

Pages